In December 2017, Janssen Research & Development, LLC announced its submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for two new Xarelto uses.
sNDA Application for New Xarelto Uses
The first use would be reducing the risk of cardiovascular (CV) death, heart attack or stroke in patients with chronic coronary artery disease (CAD), and/or peripheral artery disease (PAD). The second proposed use would be the reduction of acute limb ischemia (severe arterial blockage) risk in patients with PAD.
